Terms: = Sarcomas AND HNRNPA2B1, ENSG00000122566, SNRPB1, RNPA2, HNRPB1, HNRPA2, HNRNPB1, HNRNPA2, 3181 AND Treatment
4 results:
1. Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma.
Kundu AK; Iyer SV; Chandra S; Adhikari AS; Iwakuma T; Mandal TK
PLoS One; 2017; 12(6):e0179168. PubMed ID: 28636657
[TBL] [Abstract] [Full Text] [Related]
2. Ribonucleoprotein hnrnpa2b1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract] [Full Text] [Related]
3. [Preliminary evaluation on seroma prevention and treatment with transposition of tissue flaps and arista hemostatic powder].
Zhang R; Tan Y; Wang H
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Dec; 20(12):1220-3. PubMed ID: 17228687
[TBL] [Abstract] [Full Text] [Related]
4. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
[TBL] [Abstract] [Full Text] [Related]
